Salarius Completes FDA Type B Meeting For Seclidemstat Ewing Sarcoma Development Program
Portfolio Pulse from Benzinga Newsdesk
Salarius Pharmaceuticals has completed an FDA Type B meeting for its Seclidemstat Ewing Sarcoma development program. The meeting is a significant step in the drug's development process.
November 07, 2023 | 1:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Salarius Pharmaceuticals' completion of the FDA Type B meeting for Seclidemstat Ewing Sarcoma development program could potentially accelerate the drug's development process.
The completion of the FDA Type B meeting is a significant milestone in the drug development process. It suggests that the company is making progress in its development of Seclidemstat for Ewing Sarcoma, which could potentially lead to future revenue growth if the drug is approved. This could have a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100